Preablative stimulated thyroglobulin correlates to new therapy response system in XXXX .

@entity1 @entity1496 @entity259
CONTEXT: Studies suggested a potential value of preablative stimulated Tg (ps-Tg) on predicting the recurrent and persistent diseases of @entity259 ( @entity259 ), whereas its correlations with therapeutic response remain uncertain. OBJECTIVE: To establish the correlation between ps-Tg and therapeutic response proposed in 2015 American Thyroid Association (ATA) guidelines, and calculate a cut-off ps-Tg threshold for predicting a poor response. DESIGN/SETTING: @entity1 who underwent total thyroidectomy and radioactive @entity1496 (RAI) therapy in a University hospital participated in this retrospective study. @entity1 : Totally, 452 @entity259 @entity1 were followed for a median of 38 months and were divided into three groups in terms of ps-Tg level: Group1:<1ng/ml (n=82), Group2: 1-10ng/ml (n=173), Group3:>= 10ng/ml (n=197). MAIN OUTCOME MEASURE: Clinical outcomes were assessed based on response to therapy re-staging system, dividing response into excellent (ER), indeterminate (IDR), biomedical incomplete (BIR), and structural incomplete (SIR). RESULTS: Therapeutic responses could be obviously distinguished by different ps-Tg strata. SIR was identified in none of Group 1, 1.73% of Group 2, and 42.74% of Group 3, respectively ((2)=123.037, p<0.001). A cut-off value of ps-Tg at 26.75 ng/ml was obtained by receiver operating characteristic (ROC) curve for differentiating SIR from either ER, IDR, or BIR. The area under curve (AUC) was 0.947 and negative predictive value (NPV) was 96.99%. Ps-Tg was an independent predictive variable of SIR (OR: 42.312, p<0.001). CONCLUSIONS: Ps-Tg has a great performance in predicting therapeutic response and providing incremental value for decision making of RAI therapy, especially for @entity1 with high ps-Tg level.
